

# Longitudinal Residual Evaluations for Identifying Uterine Proliferative Lesions


Susan A. Elmore, MS, DVM, DACVP, DABT, FIATP  
NTP Pathologist  
National Institute of Environmental Health Sciences  
NTP Technical Reports Peer Review Meeting  
May 22, 2014

# Current and Prior NTP Studies that have Used the Uterine Longitudinal Sectioning Protocol

- Tetrabromobisphenol A
- Cimstar
- Green Tea Extract
- Indole-3-Carbinol
- DE-71
- 2,3 Butanedione


# Original Transverse Versus Residual Longitudinal Uterine Reviews

- Original transverse tissue review
  - Transverse section through each uterine horn
  - Cervix/vagina not processed, unless gross lesions
- Residual longitudinal tissue review
  - Remaining formalin fixed cervix, vagina, and uterine remnants were sectioned longitudinally
- Original rationale for residual longitudinal tissue review came from the tetrabromobisphenol A study
  - To determine the primary location for adenocarcinomas in the cervix and vagina
  - To review all the cervixes for hyperplasia/fibrosis





- Gross image of normal female rat reproductive organs
- Ovaries (red boxes) are attached
- Thick red horizontal lines show where a transverse cut is made through the uterine horns in the original review


# Original Review: Transverse Section From Each Uterine Horn




# Longitudinal Sections of Left and Right Uterine Horns



# Additional Sections of Longitudinal Tissue




Uterus Body




Distal Cervix




Proximal Cervix



Distal Vagina




Proximal Vagina



Vagina/Cervix Junction

**Uterus on left shows a large expansive adenocarcinoma that was detected grossly.  
Uterus on right also has an adenocarcinoma, but it was not detected grossly.**





# Tetrabromobisphenol A Study Data

Tumor	0mg/kg	250mg/kg	500mg/kg	1000mg/kg
<b>ORIGINAL TRANSVERSE REVIEW</b>				
Adenoma, Adenocarcinoma, or Malignant Mixed Müllerian Tumor	3**	7	11*	13**
<b>RESIDUAL LONGITUDINAL REVIEW</b>				
Adenoma, Adenocarcinoma, or Malignant Mixed Müllerian Tumor	6**	10	16**	16**
Atypical Hyperplasia	2	13**	11**	13**
<b>COMBINED ORIGINAL TRANSVERSE AND RESIDUAL LONGITUDINAL REVIEWS</b>				
Adenoma, Adenocarcinoma, or Malignant Mixed Müllerian Tumor	6**	11	16**	19**
Atypical Hyperplasia	2	13**	11**	13**

\* Positive trend test or significantly different ( $p \leq .05$ ) from the control group by Poly 3 test

\*\* Positive trend test or significantly different ( $p \leq .01$ ) from the control group by Poly 3 test

# Summary

- Residual longitudinal sectioning
  - Revealed additional uterine tumors, pre-neoplastic lesions, and non-neoplastic lesions in all groups
  - Was not included in the historical control data
  - Provided accurate diagnoses for some non-neoplastic lesions
    - Example: uterine dilatation due to cystic endometrial hyperplasia or uterine polyp
  - Determined primary site of invasive tumors
    - Cervix, vagina, uterus
  - Avoided misinterpretation of gross lesion incidences
    - Example: Cervical lesions
- Has been incorporated as standard protocol for NTP subchronic and chronic studies